Ponatinib
- Generic Name
- Ponatinib
- Brand Names
- Iclusig
- Drug Type
- Small Molecule
- Chemical Formula
- C29H27F3N6O
- CAS Number
- 943319-70-8
- Unique Ingredient Identifier
- 4340891KFS
- Background
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
- Indication
1.用于治疗达沙替尼或尼洛替尼治疗无效的慢性期、进展期或急性期的慢性粒细胞白血病（CML）；或不能耐受达沙替尼或尼洛替尼者，以及临床不适合用伊马替尼进行后续治疗的患者；或T315I突变者。
2.用于治疗达沙替尼治疗无效的费城染色体阳性急性淋巴细胞白血病（Ph+ALL）；或不能耐受达沙替尼者，以及临床不适合用伊马替尼进行后续治疗的患者；或T315I突变者。
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06390306
- Locations
- 🇨🇳
Peking university people's hospital, Beijing, Beijing, China
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
- Conditions
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 33
- Registration Number
- NCT06207123
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL
- Conditions
- Interventions
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 150
- Registration Number
- NCT06175702
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
- Conditions
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 220
- Registration Number
- NCT06061094
- Locations
- 🇩🇪
Department of Medicine, Hematology and Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-02-07
- Target Recruit Count
- 32
- Registration Number
- NCT05306301
- Locations
- 🇮🇹
Ematologia Policlinico A.Gemelli, Roma, Italy
🇮🇹Ematologia Ospedale S.Giovanni Battista Molinette, Torino, Italy
🇮🇹Ematologia AOU Federico II, Napoli, Italy
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
- Conditions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1484
- Registration Number
- NCT05286528
- Locations
- 🇭🇺
Pfizer, Budapest, Hungary
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT05268003
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Registration Number
- NCT04845035
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
- Conditions
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 25
- Registration Number
- NCT04747912
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Study in Adult Ph-positive ALL
- Conditions
- Interventions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Cardiff University
- Target Recruit Count
- 180
- Registration Number
- NCT04688983
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.